** Brokerage UBS raises PT on biotech firm Blueprint Medicines Corp BPMC.O to $129 from $88; setting it in line with Sanofi's buyout price for the co
** Maintains "neutral" rating
** French drugmaker Sanofi SASY.PA said on Monday it has agreed to buy BPMC for up to $9.5 billion to boost its position in rare immunology diseases
** UBS sees limited or no overlap in both companies' portfolios
** Sanofi gains Ayvakit to treat a type of rare immunology disease called advanced and indolent systemic mastocytosis with $478.9 million revenue in 2024 - UBS
** Including session's moves, stock up 46.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。